Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer.
Martin LundTorben Brøchner PedersenSøren FeddersenLouise Dorner ØstergaardCharlotte A PoulsenChristian EnggaardMads Hvid PoulsenLars LundPublished in: Research and reports in urology (2022)
Our contribution to the existing literature strengthens the idea that early in the pathological process, CCL2 mainly circulates in large, membrane-enclosed compartments, whereas plasma CCL2 levels increase markedly during disease progression. We conclude that whereas plasma CCL2 levels are not useful as a diagnostic measure, a ratio of CCL2 plasma to serum levels may prove useful as a marker of disease progression, which warrants further study.